Navigation Links
PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Date:8/6/2008

.K. regulations, the Company cannot provide more specific revenue or earnings per share guidance at this time. The Company expects to update guidance in more detail after the completion of the transaction.

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures, including operating income, pretax income, income taxes, net income, and diluted earnings per share. The Company believes that presenting the non-GAAP financial measures contained in the financial tables and in this press release assists investors and others in gaining a better understanding of its core operating results and future prospects, especially when comparing such results to previous periods or forecasted guidance, because they exclude items that are outside of the Company's normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. Management uses non-GAAP financial measures, in addition to the GAAP information, as the basis for measuring the Company's core operating performance and comparing such performance to that of prior periods and to the performance of its competitors for the same reasons stated above. Such measures are also used by management in its financial and operating decision-making. Non-GAAP financial measures are not meant to be considered superior to or a substitute for the Company's results of operations prepared in accordance with GAAP. A reconciliation of GAAP results with non-GAAP financial measures may be found in the attached financial tables.

A conference call to discuss PAREXEL's fourth quarter and year-end earnings, business, and financial outlook will begin at 10:00 a.m. EDT Thursday, August 7, 2008 and will be broadcast live over the internet via webcast. The webcast may be accessed in the "Webcasts" portion of the Investor Relations section of the Company's website at '/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer
2. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
3. PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day
4. PAREXEL Expands Global Clinical Logistics Capabilities
5. Parexel Invites Public to Listen to Live Webcast of Its Investor Day June 25, 2008
6. PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
7. PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting
8. PAREXEL Reaches Agreement To Acquire ClinPhone
9. PAREXEL International to Present at Goldman Sachs 29th Annual Global Healthcare Conference
10. PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention
11. PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine” or ... a fraudulent press release disseminated this morning by PR ... Immunovaccine. This press release states that Immunovaccine has entered ... The press release did not originate from Immunovaccine and ... the press release. Please note that all official ...
(Date:2/27/2015)... Immunovaccine Inc. (“Immunovaccine”) (TSX: IMV), ... announced that the U.S. Food and Drug Administration ... and Phase I clinical trials of the DPX-Anthrax ... co-development agreement signed with Gilead Life Sciences. The ... the DPX-Survivac. , “We have been in talks ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Cytokinetics, Incorporated ... on February 28 with patients and health care advocates ... for Rare Disease Day®. Rare Disease Day is ... calling attention to the special challenges faced by patients ... , “Cytokinetics is proud to stand alongside patients and ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015  23andMe, the ... Kate Black as Privacy Officer and Corporate ... and state privacy laws as well as health care ... team, she will be responsible for reviewing, updating and ... in the U.S. and abroad. She joined the company ...
Breaking Biology Technology:Immunovaccine Disclaims Hoax Press Release 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 623andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2
... ... ... ... ...
... ... Evonik for Industrial Biotechnology R&D Processes , ... Basel, Switzerland (PRWEB) February 23, 2010 -- ... announced an extended partnership with Evonik, a leading life science, specialty chemicals and ...
... Medicine , Susan Huang and colleagues describe the use ... by integrating two freely available software packages, to identify ... data from patients admitted to a 750-bed academic medical ... authors found that the tool identified a number of ...
Cached Biology Technology:Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology 2Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology 3Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology 4Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology 5Barnes-Jewish Hospital to Provide Gamma Knife Surgery to Additional Patient Groups With New Elekta Technology 6Evonik Extends Long-term Research & Development Partnership with Genedata 2Evonik Extends Long-term Research & Development Partnership with Genedata 3Evonik Extends Long-term Research & Development Partnership with Genedata 4Tool identifies infection clusters; rate of T cell drop not helpful in decision to start treating HIV 2Tool identifies infection clusters; rate of T cell drop not helpful in decision to start treating HIV 3Tool identifies infection clusters; rate of T cell drop not helpful in decision to start treating HIV 4
(Date:2/5/2015)... New Market Research Reports Title ... To 2020 has Been Added to GrandViewReseach.com Report Database ... to reach USD 5.10 billion by 2020, according to ... cameras help identify the site of tissue damage in ... demand in medical imaging applications. They have been extensively ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
(Date:1/22/2015)... Jan. 15, 2015  BellBrook Labs, a leader in ... the launch of a TR-FRET (time resolved Forster ... UDP Assay, a high throughput screening assay for ... will allow for sensitive detection of hundreds of ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Mother Nature by developing, for the first time, ... tiny, hair-like structures through which organisms derive smell, ... new material isn,t exactly like cilia, it responds ... to control it and opening unlimited possibilities for ...
... BOSTONDana-Farber Cancer Institute,s Belfer Institute of Applied ... and NYSE: SNY) announced today that they have ... to identify and validate novel oncology targets ... novel therapeutics agents directed to such targets and ...
... Edward Yu of Iowa State University and the Ames Laboratory ... metal toxins from bacteria, making them resistant to antibiotics. ... of the journal Nature . Yu an ... of biochemistry, biophysics and molecular biology and an associate of ...
Cached Biology News:Cilia revolution 2Dana-Farber and sanofi-aventis establish cancer research alliance 2Iowa State, Ames Lab researchers identify structure that allows bacteria to resist drugs 2
... from E. coli is a ... also contains both 5'--3'and 3'--5' ... activity enables the enzyme to ... the DNA as starting points ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... thymus Description: Topoisomerase I relaxes both ... breakage and rejoining of phosphodiester bonds (1,2) . ... to be differentiated by a single nucleotide pair ... active in the absence of Mn 2+ ...
...
Biology Products: